NEUE · As filed with the SEC

NeueHealth balance sheet, by fiscal year

The statement as NeueHealth presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

CONSOLIDATED BALANCE SHEETS · USD thousands

USD thousands	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021
Assets
Current assets:
Cash and cash equivalents	83,295	87,299	466,325	1,061,179
Short-term investments	9,871	6,265	13,206	193,835
Accounts receivable, net of allowance of $27 and $14,023, respectively	36,594	39,084	73,605	113,474
Direct contracting performance year receivable	—	—	99,181	—
ACO REACH performance year receivable	95,075	115,878	—	—
Current assets of discontinued operations (Note 19)	173,006	822,570	2,783,474	—
Discontinued Operations	173,006	—	—	—
Prepaids and other current assets	36,807	17,831	134,843	291,712
Total current assets	434,648	1,088,927	3,570,634	1,660,200
Other assets:
Long-term investments	—	0	5,401	675,192
Property, equipment and capitalized software, net	11,240	14,499	42,596	38,344
Goodwill	—	0	760,078	835,140
Intangible assets, net	71,064	93,238	249,083	343,860
Long-term assets of discontinued operations (Note 19)	—	0	0	—
Other non-current assets	27,431	28,816	37,260	45,603
Total other assets	109,735	136,553	1,094,418	1,938,139
Total assets	544,383	1,225,480	4,665,052	3,598,339
Liabilities, Redeemable Noncontrolling Interests, Redeemable Preferred Stock and Shareholders’ Equity (Deficit)
Current liabilities:
Medical costs payable	124,360	157,903	411,753	817,975
Accounts payable	6,298	11,841	67,854	118,140
Unearned revenue	—	—	242	53,295
Risk adjustment payable	—	—	—	931,170
Short-term borrowings	2,000	303,947	303,947	155,000
Current liabilities of discontinued operations (Note 19)	—	699,758	2,783,474	—
Discontinued Operations	344,651	—	—	—
Risk share payable to deconsolidated entity	123,981	123,981	—	—
Warrant liability	29,738	13,971	—	—
Other current liabilities	79,200	79,856	121,424	207,238
Total current liabilities	710,228	1,391,257	3,688,694	2,282,818
Long-term borrowings	—	66,400	—	—
Total long-term borrowings	202,614	—	—	—
Other liabilities	17,649	22,441	36,673	41,994
Total liabilities	930,491	1,480,098	3,725,367	2,324,812
Redeemable noncontrolling interests	48,580	88,908	219,758	128,407
Redeemable Series A and B preferred stock	920,417	920,417	920,417	0
Redeemable Series A preferred stock	747,481	747,481	747,481	—
Redeemable Series B preferred stock	172,936	172,936	172,936	—
Shareholders’ equity (deficit):
Common stock, $0.0001 par value; 3,000,000,000 shares authorized in 2024 and 2023; 8,320,959 and 8,053,576 shares issued and outstanding in 2024 and 2023, respectively	1	1	63	63
Additional paid-in capital	3,099,423	3,056,027	2,972,271	2,861,243
Accumulated deficit	(4,442,529)	(4,307,849)	(3,156,395)	(1,700,851)
Accumulated other comprehensive loss	0	(122)	(4,429)	(3,335)
Treasury stock, at cost, 2,522,148 and — shares at December 31, 2021 and 2020, respectively	—	—	—	(12,000)
Treasury stock, at cost, 31,526 shares at December 31, 2024 and 2023	(12,000)	(12,000)	(12,000)	—
Total shareholders’ equity (deficit)	(1,355,105)	(1,263,943)	(200,490)	1,145,120
Total liabilities, redeemable noncontrolling interests, redeemable preferred stock and shareholders’ equity (deficit)	544,383	1,225,480	4,665,052	3,598,339

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.